PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/758864
Filing Date	January 16, 2004 (Herewith)
First Named Inventor	Erik H.F. Wong
Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	30744/6248.11

U.S. PATENT DOCUMENTS

Examiner Initials*	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Date Filed if Appropriate
PS	4,229,449	10-21-80	Melloni et al.	
	4,596,807	06-24-86	Crosby	
	5,068,433	11-26-91	Melloni et al.	
	5,192,751	03-09-93	Thor	
	5,281,624	01-25-95	Gehlert et al.	
	5,391,735	02-21-95	Melloni et al.	
	5,441,985	08-15-95	Foreman	
	5,744,474	04-28-98	Thor	
	5,922,914	07-13-99	Gage et al.	
	5,998,430	12-07-99	Schwantes et al.	
	6,028,070	02-22-00	Heiligenstein	
	6,046,193	04-04-00	Heiligenstein	
	6,066,643	05-23-00	Perry	
	4,465,458	10-15-02	Wong et al.	
	6,610,690	08-26-03	Wong et al.	
	6,642,235	11-04-03	Wong et al.	
	2002-0061910-A1	05-23-02	Wong et al.	12-14-01
	2002-0107249-A1	08-08-02	Wong et al.	01-23-02
	2003-0040464-A1	02-27-03	Wong et al.	09-26-02

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Patent Document Country Code-Number-Kind Code *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
PS	2,014,981	09-05-79	Great Britain	
	2,167,407	05-11-88	Great Britain	
	WO 96/12485	05-02-96	PCT	
	WO 97/35584	10-02-97	PCT	
	WO 97/35586	10/02/97	PCT	
	WO 99/15163	04-01-99	PCT	
	WO 99/15176	04-01-99	PCT	
	WO 99/15177	04-01-99	PCT	
	WO 99/20279	04-29-99	PCT	
	WO 99/52531	10-21-99	PCT	
	WO 99/52518	10-21-99	PCT	
	WO 99/58130	11-18-99	PCT	
	WO 01/26623	04-19-01	PCT	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
PS	J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence, Am. J. of Psychiatry, Vol. 122, pp. 509-22 (Nov. 1965).	
PS	T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: a-Receptor Mediation, Science, Vol. 202, pp. 1089-91 (1984).	

Phyllis Spivack 10/16/05

PTO/SB/08B (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	3

Complete if Known	
Application Number	10/758,864
Filing Date	January 16, 2004 (Herewith)
First Named Inventor	Erik H.F. Wong
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	30744/6248.11

PS	E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake, Europ. J of Pharmacology, Vol. 104 pp. 277-86 (1984).	
	C.B. Nemeroff, The Neurobiology of Depression, Scientific American (1988) (8 pages).	
	M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, J. Drug Dev., Vol. 1, no. 4, pp. 243-53 (1989).	
	T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, Nature, Vol. 350, no. 28, pp. 350-56 (March 1991).	
	M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, Pain, Vol. 45, pp. 3-9 (1991).	
	E. Richelson, Biological Basis of Depression and Therapeutic Relevance, J. Clin. Psychiatry, Vol. 52, no. 6 Suppl., pp. 4-10 (June 1991).	
	M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, New Engl. J. Med., Vol. 326, No. 19, pp. 1250-56 (1992).	
	B. Cusack et al., Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, Psychopharmacology, Vol. 114, pp. 559-65 (1994).	
	M. Max, "Treatment of Post-Herpetic Neuralgia: Antidepressants," Ann. Neurol., Vol. 35, Suppl., pp. s50-s53 (1994).	
	W. Reimann et al., "Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol," Biochem. Pharmacol., Vol. 47, No. 12, pp. 2289-93 (1994).	
	C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Against Repeated Oral Doses and Lack of Enzymatic Alterations, Biopharm. Drug Dispos. Vol. 17. No. 7, pp. 623-33 (1996).	
	R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Chapter 19, pp. 431-39, (1996)	
	B.E. Leonard, Noradrenaline in Basic Models of Depression, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S11-S16 (1997).	
	Discussion, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S71-S73 (1997).	
	S.A. Montgomery, Is There a Role For a Pure Noradrenergic Drug in the Treatment of Depression?, Eur. Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S3-S9 (1997).	
	S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Patient, J. Psychopharmacology (Oxf), 11:4 Abstract (1997).	
	I. Hindmarch, The Effects of Antidepressants on Psychomotor Function With Particular Reference to Reboxetine, Eur. Neuropsychopharmacology, Vo. 7, Suppl. 1, pp. S17-S21 (1997).	
	E. Frigerio et al., Pharmacokinetics of Reboxetine Enantiomers in the Dog, Chirality, Vol. 9, pp. 303-06 (1997).	
	A. Frazer, Pharmacology of Antidepressants, J. Clinical Psychopharmacology, Vol. 17, no. 2, Suppl. 1, pp. 2S-18S (1997).	
	B. E. Leonard, The Role of Noradrenaline in Depression: a Review, J. Psychopharmacology, Vol. II, no. 4 Suppl., pp. S39-S47 (1997).	

Phyllis Spivack 10/16/05

PTO/SB/08B (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3

Complete if Known	
Application Number	10/758,614
Filing Date	January 16, 2004 (Herewith)
First Named Inventor	Erik H.F. Wong
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	30744/6248.11

PS	Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor," Euro. Neuropsychopharmacol., Vol. 7, Suppl. 1, pp. s23-s35 (1997).	
	M. Owens et al., "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites," J. Pharmacol. Exp. Ther., Vol. 283, pp. 1305-1322 (1997).	
	D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, J. of Affective Disorders, Vol. 51, pp. 313-22 (1998).	
	Anonymous, Reboxetine – Another New Antidepressant, Drugs and Therapeutics Bull., 36 (11) (1998).	
	S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, J. of Clinical Psychiatry, Vol. 59, Suppl. 14, pp. 26-29 (1998).	
	G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, J. Clin. Psychiatry, Vol. 59, Suppl. 14, 4 pages (1998).	
	J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, J. Clin. Psychiatry, Vol. 59, Suppl 14, pp. 8-10 (1998).	
	A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination With Sertraline in an Animal Model of Depression, Eur. J. of Pharmacology, pp. 1-10 (1998).	
	J. Massana et al., Reboxetine: A Double-Blind Comparison With Fluoxetine in Major Depressive Disorder, Int. Clin. Psychopharmacol, Vol. 14. No. 2, pp. 73-80 (1999).	
	J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, Biopharm. Drug Dispos. Vol. 20, no. 1, pp. 53-57 (1999).	
	K. Moore et al., "Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality," Am. J. of Forensic Med. and Path., Vol. 20, No. 1, pp. 98-100 (1999).	
	S. Kasper, From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy, International Clinical Psychopharmacology, Vol. 14, Suppl. 1, pp. S27-S31 (May 1999).	
	J. Mark Ruscin and Nora E. Morgenstern, "Tolterodine Use for Symptoms of Overactive Bladder," The Annals of Pharmacotherapy, Abstract Vol. 33, pgs. 1073-82 (October 1999).	
	International Search Report in PCT/US00/17256 dated July 12, 2001.	
	International Preliminary Examination Report in PCT/US00/17256 dated December 19, 2001.	
	"Notice of Allowance and Fee(s) Due" dated March 25, 2003, sent by the United States Patent and Trademark Office for U.S. Serial No. 10/037,344 (4 pages).	

Examiner Signature	Phyllis Spivack	Date Considered	10/16/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Form PTO-1449 (Modified)	Atty. Docket No. 30744/6248.11	Serial No. 10/758,864
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	Applicants Wong et al.	
	Filing Date January 16, 2004	Art Unit 1614

AUG 30 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Sub class	Filing Date (If Appropriate)
PS	6,290,986	09/18/2001	Murdock et al.	424	449	06/29/1998
PS	6,479,074	11/12/2002	Murdock et al.	424	449	06/29/1998
PS	6,572,880	06/03/2003	Murdock et al.	424	449	01/03/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
PS	WO 00/00120	01/06/2000	PCT		
PS	WO 01/62236	08/30/2001	PCT		
PS	WO 99/11208	03/11/1999	PCT		

Examiner Initials	OTHER DOCUMENTS (Author, Title, Journal, Volume, Pages, and Date)
PS	Mucci, M., "Reboxetine: A Review of Antidepressant Tolerability," *Journal of Psychopharmacology, Oxford University Press*, 11(4):533-537 Supp, 1997.
	~~Search Report in counterpart EP 04013383.7-2123, dated July 22, 2004 (4 pages).~~

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 10/16/05

Form PTO-1449 (Modified)	Atty. Docket No. 30744/6248.11	Serial No. 10/758,864
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	Applicants Wong et al.	
	Filing Date January 16, 2004	Art Unit 1614

OIPE SEP 1 0 2004 PATENT & TRADEMARK OFFICE SC1116

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Sub class	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
PS	WO 01/47503	07/05/2001	PCT		

Examiner Initials	OTHER DOCUMENTS (Author, Title, Journal, Volume, Pages, and Date)
	~~Search Report in counterpart EP 04013382.9-2123, dated July 22, 2004 (4 pages).~~

EXAMINER: P. Spivack	DATE CONSIDERED: 10/16/05